Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT03560856Phase 2Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of palbociclib in Hormone-Receptor-Positive Breast Cancer, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
palbociclib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT03560856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03560856.